New Data Demonstrates Potential for Oral IL-23 in Psoriasis

Dr. Laura Korb Ferris, MD, PhD, Professor, University of Pittsburgh Clinical and Translational Science Institute and Director of Clinical Trials, UPMC Department of Dermatology discusses the new phase 2b FRONTIER 1 study data that demonstrates the potential of JNJ-2113, the novel first and only oral IL-23 antagonist peptide to “potentially change the treatment paradigm” for patients with moderate to severe plaque psoriasis. She talks about why this data may be encouraging for patients and prescribers.

Laura Ferris, MD, PhD, joined the Department of Dermatology in 2006, after completing her Dermatology Residency and Investigative Dermatology Fellowship at the University of Pittsburgh.   Dr. Ferris earned her undergraduate degree in biology, from Marquette University; she completed her PhD in Immunology at Johns Hopkins Medical School, and received her medical degree from the University of Maryland.    Dr. Ferris practices general medical dermatology with a special focus on skin cancer and psoriasis. She also directs the Clinical Trials Unit in the Department of Dermatology and has served as a principal investigator on more than 30 clinical trials in Dermatology, primarily in the area of new treatments for psoriasis. She has been an invited speaker at several national and international meetings and has published more than 60 book chapters and articles in the peer-reviewed literature.